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1. INTRODUCTION
Lipocalin-type prostaglandin (PG) D synthase (L-PGDS, EC
5.3.99.2) catalyzes the isomerization of PGH2, a common
precursor of various prostanoids, to produce PGD2 and is
involved in the regulation of pain
1 and of nonrapid eye move-
ment sleep in the central nervous system,
2 the sex diﬀerentiation
of male genitals,
3 the cardiovascular function in the heart and
blood vessels,
4,5 the adipocyte diﬀerentiation,
6 and the modula-
tion of renal function.
7 L-PGDS, also known as beta-trace, is the
major protein in human cerebrospinal ﬂuid; binds to various
lipophilic ligands such as retinoids, thyroids, bilirubin, and
biliverdin with high aﬃnities; and is the only enzyme in the
lipocalin superfamily, which is composed of various secretory
lipid-transporter proteins.
8 Hematopoietic PGD synthase
(H-PGDS) catalyzes the same reaction but is quite diﬀerent
fromL-PGDSintermsofaminoacidsequence,tertiarystructure,
cellular distribution, inhibitor sensitivity, etc.
9 Nonsteroidal anti-
inﬂammatory drugs such as indomethacin and aspirin suppress
inﬂammatory reactions by inhibiting PGH2 synthase/cyclooxy-
genase; decrease the production of all types of prostanoids,
including cytoprotective and anti-inﬂammatory PGs; and induce
adverse eﬀects.
10,11 An inhibitor of L-PGDS may selectively
suppress the pain or drowsiness mediated by L-PGDS-catalyzed
PGD2 without various side eﬀects.
Although many biochemical studies suggest that PGD2 and
L-PGDS play important roles in a variety of physiological and
pathological functions, the crystallization of wild-type L-PGDS was




189 during the expression of the recombinant
protein.
12 To produce a correctly folded L-PGDS with an S S
linkage between Cys
89 and Cys
189, the putative catalytic residue
Cys
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diﬀerentiation of male genital organs and adipocytes, etc. L-PGDS is
secreted into various body ﬂuids and binds various lipophilic compounds
with high aﬃnities, acting also as an extracellular transporter. Mouse
L-PGDS with a C65A mutation was previously crystallized with citrate or
malonate as a precipitant, and the X-ray crystallographic structure was
determined at 2.0 Å resolution. To obtain high-quality crystals, we tried,
unsuccessfully, to crystallize the C65A mutant in microgravity under the
same conditions used in the previous study. After further purifying the
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high-quality crystals were grown in microgravity. The precipitant solution
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activity was used in a previous crystallization study and crystallized
with malonate or citrate as a precipitant.
13 The X-ray crystal-
lographic structure of the C65A mutant was determined at a res-
olution of 2.0 Å
14.
In this study, we focused on the high-quality crystallization of
wild-type mouse L-PGDS. After optimization of the crystal-
lization conditions and the sample preparation, we ﬁnally ob-
tained high-quality crystals, which diﬀracted up to 0.98 Å.
We also crystallized the C65A mutant of mouse L-PGDS using
the same procedure and obtained crystals, which diﬀracted
beyond 1.16 Å. Both of the crystals were grown in microgravity
andwereimprovedinqualitywhencomparedtothose grown on
the ground using the same crystallization conditions. These
results suggested that the microgravity environment positively
aﬀected the growth of high-quality crystals of this protein.
2. EXPERIMENTAL SECTION
2.1. Protein Expression and Purification of Wild-Type
Mouse L-PGDS and Its C65A Mutant. The cDNAs of wild-type
mouse L-PGDS without its N-terminal signal peptide of 24 amino acids
and its C65A mutant were expressed in Escherichia coli BL21(DE3)
(Invitrogen, CA, USA) as a glutathione (GSH) transferase-fusion
protein. The fusion protein was purified by GSH-Sepharose 4B (GE
Healthcare, Buckinghamshire, U.K.) column chromatography from a
soluble fraction of E. coli cells. After incubation with thrombin (Sigma-
Aldrich, WI, USA), L-PGDS protein was obtained and further purified
by column chromatography on Superdex 75 (GE Healthcare) in 5 mM
Tris-HCl pH 8.0, followed by Mono-S HR5/5 (GE Healthcare)
chromatography with a linear gradient from 0 to 500 mM sodium
chloridein20mMTris-HCl,pH7.5,at293K.Structuralhomogeneities
of final purified preparations of the wild-type and C65A mutant of
mouse L-PGDS were evaluated by SDS-PAGE (under reducing con-
ditions)andbynative PAGE(PAGEwithoutadenaturingreagent, such
as SDS, and under nonreducing conditions) as shown in Figure 1. The
wild-type L-PGDS showed the same PGDS activity as that of the
C89,189A mutant.
14 They were concentrated to 40 mg mL
 1 in
100 mM HEPES-NaOH, pH 7.0, and 100 mM sodium chloride using
aCentricon YM-10 membrane(10,000 nominalmolecular weightlimit;
Millipore, MA, USA) and stored at 277 K. The protein concentration
was determined spectrophotometrically at 280 nm.
2.2. Crystallization. Wild-type mouse L-PGDS and its C65A
mutant were crystallized inside the Russian TBU incubator on board
theRussianServiceModuleontheInternationalSpaceStation(ISS)for
11 weeks from August to October, 2007, as a microgravity experiment
supported by the Japan Aerospace Exploration Agency (JAXA).
Thetemperaturewaskeptat293(1KintheTBUfortenweeks,but
it rose to 298 ( 1 K for 90 min in the Soyuz Spacecraft on the return
ﬂight. The highest temperature was 299 K. Although the temperature
becamehighenoughtodamagesomeproteinsamples,theproteininthis
report was suﬃciently stable even at 299 K.
A gel-tube method,
15 modiﬁed from the original counterdiﬀusion
method,
16 18 was used for crystallization, as described.
19 Brieﬂy, the
protein solution (8 μL, 40 mg mL
 1 protein, 100 mM sodium chloride,
and 100 mM HEPES-NaOH, pH 7.0) was added to a glass capillary
(47 mm length, 0.5 mm diameter) to a length of 40 mm. The end of the
capillary was attached to a plastic tube (gel-tube, 3 mm length), which
contained 1% polymerized agarose gel presoaked in 20% (w/v) PEG
8000, 100 mM sodium chloride, and 100 mM HEPES-NaOH, pH 7.0.
The top of the capillary was sealed with clay and epoxy adhesive. The
agarose-end of the capillary was placed in a tube, which contained the
precipitant solution of 40% PEG 8000, 100 mM sodium chloride, and
100 mM HEPES-NaOH, pH 7.0. These conditions were ﬁxed to start
crystallization after the samples had been placed in the microgravity
environment by adjusting the precipitant concentration, the gel-tube
length, and the composition of the presoaked solution of the gel-tube.
Thesamecrystallizationconditionswereusedinthecontrolexperiment
on the ground.
2.3. Data Collection and Analysis. Diffraction data were col-
lected at 100 K with an X-ray wavelength of 0.9 Å on the BL41XU
beamline at SPring-8, Harima, Japan, using an ADSC315 detector
system. No additional cryoprotectant was needed, since the concentra-
tion of PEG 8000 in the mother liquor was high enough to act as a
cryoprotectant. The method of harvesting crystals from the capillaries
hasbeenreportedpreviously.
20Briefly,toharvestacrystal,thesectionof
the capillary tube containing the desired crystal was cut out with a
capillary cutting stone. Then a gentle flow of harvest solution from a
micropipetwasusedtowashthecrystaloutofthecapillarysegmentinto
harvest solution in a concave slide glass with a single depression well.
One crystal was extracted with a nylon loop and plunged directly into a
nitrogen-gasstreamat100K.Atotalof180frameswerecollectedusinga
crystal-to-detector distance of 130 mm with 1 oscillation. The diffrac-
tion images were integrated and scaled using the programs DENZO and
SCALEPACK from the HKL-2000 suite.
21
Figure 1. (a) SDS-PAGE ofwild-type mouse L-PGDS (lane 1)and the
C65Amutant(lane2)underreducingconditions.Themolecularweight
markerproteinsareindicatedintherightlane.(b)Native-PAGEofwild-
type mouse L-PGDS (lane 1) and the C65A mutant (lane 2) under
nonreducing conditions. Bands of marker protein (pI = 4.4) are shown
on both sides.2109 dx.doi.org/10.1021/cg101370v |Cryst. Growth Des. 2011, 11, 2107–2111
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3. RESULTS AND DISCUSSION
Native-PAGE of the wild-type L-PGDS, puriﬁed by the pre-
viouslyreportedmethod,
13showedaminorbandwithanincorrect
S S linkage. Therefore, we changed the elution condition of the
recombinant protein through Mono-S chromatography and ob-
tained highly puriﬁed wild-type L-PGDS and the C65A mutant.
Figure 1 shows SDS-PAGE and native-PAGE of the ﬁnal puriﬁed
homogeneous samples used for crystallization.
Crystals started growing in the capillaries 2 to 3 weeks after
sample loading on the ground. The crystals we obtained are
shown in Figure 2. In microgravity, we obtained rodlike crystals
of the wild-type L-PGDS (1.0   0.1   0.1 mm
3, Figure 2a) and
the C65A mutant (0.5   0.1   0.1 mm
3, Figure 2b) along the
capillaries. While, on the ground, thin, platelike crystals of the
wild-type L-PGDS (0.4   0.1   0.05 mm
3, Figure 2c) and the
C65A mutant (0.5   0.3   0.05 mm
3, Figure 2d) were grown in
the capillaries. Crystals of wild-type mouse L-PGDS were
obtained for the ﬁrst time.
For X-ray diﬀraction data collection, we selected crystals
grown on the opposite side of the gel-tube in the capillaries,
becausecrystalsofbetterqualitytendtogrowonthisside,where
the precipitant concentration changes slowly.
22 All crystals
chosen for X-ray diﬀraction data collection were judged to be
of suﬃcient size and of good quality by visual inspection. To
avoid ﬂuctuations in the data caused by diﬀerences in the crystal
size, we chose crystals similar in size. However, crystals of the
C65A mutant grown on the ground were too thin and fragile to
carry out the diﬀraction experiment even at the synchrotron site.
TheX-raydiﬀractiondataaresummarizedinTable1.Crystals
of wild-type L-PGDS obtained with PEG 8000 as a precipitant
in microgravity belonged to the primitive orthorhombic space
group P21212, with unit-cell dimensions of a = 62.3, b =
67.0, and c = 35.7 Å. We collected a diﬀraction data set up to
1.06 Å (the maximum resolution of approximately 0.98 Å).
Crystals of the wild-type enzyme grown on the ground belonged
to the same space group as those grown in microgravity, with
unit-cell dimensions of a = 62.2, b = 67.0, and c = 35.6 Å. We
collected a diﬀraction data set up to 1.30 Å (the maximum
resolutionofapproximately1.29Å).Themosaicityofthecrystals
grown in microgravity was reduced to 0.16 when compared to
themosaicityofthecrystalsgrownontheground(0.35).Crystals
of the C65A mutant obtained with PEG 8000 as a precipitant
in microgravity belonged to the same space group as those of
the wild-type enzyme, with unit-cell dimensions of a = 62.2, b =
66.2, and c = 35.5 Å. We collected a diﬀraction data set up to
1.16 Å (mosaicity: 0.20).
There are four variables in this report: the crystallization
method (counterdiﬀusion vs vapor-diﬀusion); the protein sam-
ple homogeneiety (high vs comparatively low); the precipitant
(PEG 8000 vs sodium malonate); and the crystallization envir-
onment (space vs ground). All of these may contribute to the
improvement of crystal quality. In this study, we elucidated that
the variables positively work to obtain high quality crystals.
In the previously reported method, 2M sodium malonate was
used as a precipitant with a less homogeneous protein sample of
mouse L-PGDS C65A mutant using the vapor-diﬀusion method
on the ground. However, the crystallization probability was low,
and even when we obtained a crystal, it diﬀracted X-rays up to
only 2.0 Å.
14 When we applied the same crystallization condi-
tions to the counterdiﬀusion method on the ground, it yielded
similar results of low crystallization probability, although the
counterdiﬀusion method has been reported to improve crystal
quality in some cases.
23 We also used these crystallization
conditions in JAXA’s high-quality protein crystallization project
(JAXA-GCF) in microgravity three times in 2003, 2004, and
2005, but no crystal was obtained.
We have previously demonstrated in the crystallization of
H-PGDS
19,24 that a low diﬀusion coeﬃcient (D) and a high
kinetic constant for crystal growth (β) enhance the microgravity
eﬀect on crystallization. Thus, we further puriﬁed the L-PGDS
sample used for crystallization to increase the β index
25 by
reducing impurities which interfere with the growth of crystals.
The puriﬁed sample was used for the crystallization experiment
withsodiummalonateasaprecipitantbothonthegroundandin
Figure 2. (a) Crystals of wild-type L-PGDS grown in microgravity.
(b) Crystals of the C65A mutant grown in microgravity. (c) Crystals of
wild-type L-PGDS grown on the ground. (d) Crystals of the C65A
mutant grown on the ground. The scale bars correspond to 100 μm.2110 dx.doi.org/10.1021/cg101370v |Cryst. Growth Des. 2011, 11, 2107–2111
Crystal Growth & Design ARTICLE
microgravityinthesameﬂightasthefollowingexperiment,yetthe
crystalsgrowninbothenvironmentsdiﬀractedX-rays up to 2.3Å.
We then increased the viscosity of the crystallization solution
by the usage of PEG 8000 as a precipitant to decrease the D
index.
26 Using PEG 8000 instead of sodium malonate with an
optimum salt concentration
27 remarkably improved the quality
of the crystal grown on the ground (maximum resolution
1.30 Å, mosaicity 0.35), probably because the space group of the
crystal grown in the PEG 8000 solution (P21212) was diﬀerent from
the one grown in sodium malonate solution (C2221). The crystal-
lizationprobabilityalsoincreasedtonearly100%inthePEGsolution,
which ensured successful crystallization in microgravity.
The use of PEG 8000 as a precipitant also signiﬁcantly im-
proved the crystal quality in microgravity. So far to date, we have
obtained the best wild-type mouse L-PGDS crystals for this
protein indexed by the maximum resolution (beyond 1.0 Å) and
the minimum mosaicity (0.16). Structural reﬁnement of this
diﬀraction data is currently in progress.
Our results suggested that crystal quality was improved, mainly
due tothe useofPEG8000solution,especiallyinmicrogravity, in
combination with the usage of the puriﬁe dp r o t e i ni nt h i ss t u d y .
Thequalityimprovementisthoughttobetheresultoftheﬁltering
eﬀects of the concentration depletion zones of protein and im-
purityaroundthecrystals,
28 30whichwerestronglyenhancedbya
high-viscosity PEG solution in a convection-free environment
such as microgravity.
26,31
There are some reports which introduce the opinion that the
addition of agarose gel to a crystallization solution can mimic the
eﬀects of microgravity.
32 Therefore, we tried a crystallization experi-
ment in this gel. However, the optimization of the crystallization
condition was not successful and we could not obtain any crystals.
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